PW
Walker, Paul Richard
Affiliation entities
Research groups
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences | 2025 | 165 | 75 | |||
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | 2024 | 293 | 256 | |||
| Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro | Radiotherapy and oncology | 2024 | 107 | 28 | |||
| Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming | International journal of molecular sciences | 2024 | 101 | 85 | |||
| Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | 2024 | 132 | 62 | |||
| Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy | Clinical and Experimental Medicine | 2024 | 98 | 42 | |||
| How to outsmart the cold tumor microenvironment: Design of STING ligand nanoparticles for improved cancer immunotherapy | OpenNano | 2023 | 77 | 29 | |||
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | 2023 | 323 | 115 | |||
| Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition | Neuro-oncology | 2022 | 288 | 148 | |||
| Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors | Pharmaceutics | 2022 | 253 | 85 | |||
| An update on actively targeted liposomes in advanced drug delivery to glioma | International journal of pharmaceutics | 2021 | 189 | 1 | |||
| Glioma-Derived Extracellular Vesicles - Far More Than Local Mediators | Frontiers in immunology | 2021 | 213 | 157 | |||
| Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma | Journal for immunotherapy of cancer | 2021 | 276 | 212 | |||
| Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin) | JCI insight | 2021 | 262 | 152 | |||
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | 2021 | 342 | 200 | |||
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | 2020 | 483 | 306 | |||
| Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer | Journal of Controlled Release | 2020 | 285 | 242 | |||
| Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review | Journal for immunotherapy of cancer | 2020 | 200 | 266 | |||
| Harnessing Microglia and Macrophages for the Treatment of Glioblastoma | Frontiers in Pharmacology | 2019 | 464 | 296 | |||
| Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine | JCI Insight | 2019 | 308 | 3 | |||
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | 2019 | 846 | 561 | |||
| Peptides as cancer vaccines | Current Opinion in Pharmacology | 2019 | 424 | 4 | |||
| Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models | OncoImmunology | 2018 | 433 | 1 | |||
| Let there be oxygen and T cells | Journal of Clinical Investigation | 2018 | 393 | 181 | |||
| Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines | Cellular and Molecular Life Sciences | 2018 | 398 | 192 | |||
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | 2018 | 665 | 351 | |||
| Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | 2017 | 424 | 0 | |||
| Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes | EMBO Reports | 2017 | 595 | 4 | |||
| ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells | EMBO Journal | 2017 | 622 | 10 | |||
| Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | 2016 | 533 | 442 | |||
| Cell-penetrating peptides-the Swiss Army knife of cancer vaccines | Oncoimmunology | 2016 | 650 | 319 | |||
| Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes | PloS one | 2016 | 576 | 239 | |||
| Hypoxia and antitumor CD8(+) T cells: An incompatible alliance? | OncoImmunology | 2016 | 489 | 347 | |||
| Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing | PloS one | 2016 | 668 | 652 | |||
| Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants | Molecular therapy | 2016 | 677 | 346 | |||
| Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells | European Journal of Immunology | 2015 | 553 | 7 | |||
| Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity | Cancer research | 2015 | 644 | 10 | |||
| Immunotherapy of Brain Tumors | Progress in tumor research | 2015 | 585 | 0 | |||
| The CD40/CD40L axis in glioma progression and therapy | Neuro-oncology | 2015 | 498 | 213 | |||
| Immunotherapy for glioma: from illusion to realistic prospects? | American Society of Clinical Oncology educational book | 2014 | 1,275 | 634 | |||
| Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours | PloS one | 2013 | 729 | 328 | |||
| The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity | Journal of neuroinflammation | 2013 | 630 | 359 | |||
| Getting by with a little help from the right CD4+ T cells | Oncoimmunology | 2013 | 571 | 247 | |||
| Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies | Immunotherapy | 2013 | 546 | 0 | |||
| Macrophages and Microglia in Brain Malignancies | Tumor Microenvironment and Myelomonocytic Cells | 2012 | 536 | 638 | |||
| Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy | Brain | 2012 | 707 | 1,433 | |||
| Oncology ESAB 2011 | 2011 | 683 | 10 | ||||
| Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development | Cancer research | 2010 | 619 | 3 | |||
| T-cell immunotherapy for malignant glioma: toward a combined approach | Current opinion in oncology | 2010 | 665 | 2 | |||
| Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes | GLIA | 2008 | 663 | 11 |
